HealthTech Technology Leadership.
Technology leadership where patient safety is not a feature. It is the entire foundation, in every jurisdiction.
Where Clinical Risk Shapes Every Decision, Across Borders
Healthcare technology operates under a pressure that most sectors never encounter. A bug in a SaaS product loses someone a few minutes. A bug in a clinical system can lose someone their health. That asymmetry shapes everything: how you architect, how you test, how you deploy, and how you build your team. In European healthtech, that pressure is multiplied by the complexity of operating across jurisdictions where regulatory frameworks differ in substance, not just in language.
The European regulatory landscape for healthtech is layered and fragmented by design. The EU Medical Device Regulation (EU MDR 2017/745) and the In Vitro Diagnostic Regulation (IVDR) set the baseline for CE marking and market access. The European Health Data Space (EHDS) is reshaping how health data flows across borders. GDPR governs the most sensitive category of personal data, with national data protection authorities interpreting it differently: the CNIL in France, the BfDI in Germany, the Garante in Italy, the AP in the Netherlands, the DPC in Ireland. And beneath this European layer, national health systems impose their own technical and clinical standards.
Those national frameworks differ enormously. Germany's Digital Health Applications Regulation (DiGA) has created a structured pathway for prescribable digital health applications, complete with BfArM assessment and interoperability requirements. France's Haute Autorite de Sante (HAS) evaluates clinical software through a different lens entirely. Sweden's Patient Data Act governs how clinical information systems handle patient records. The Dutch NZa regulates digital care pathways. Ireland's HPRA oversees medical devices and SaMD, while HIQA sets standards for health information quality and digital health. Each country represents a distinct regulatory surface, and healthtech companies operating across borders must navigate several simultaneously.
Most technology leaders encounter one or two of these frameworks in their career. In European healthtech, you face several at once, often with a small team and limited budget. The founders and investors we work with need technology leadership that understands these constraints from operational experience. They need someone who has built systems to meet CE marking requirements, navigated health data governance across jurisdictions, and shipped clinical software into environments where uptime is not a KPI but a duty of care. That is where our fractional CTO offering is most relevant.
We operate as practitioners who have built and run healthcare technology across clinical, pharmaceutical, care, and digital health settings. For investors acquiring UK healthtech companies, we bring deep NHS and MHRA expertise. For those assessing Continental or Nordic assets, we understand the local regulatory landscape with the same depth.
“In healthcare, the cost of a production incident is not measured in lost revenue. It is measured in patient safety. That changes how you build everything, in every jurisdiction.”
What We See in European HealthTech
Clinical safety treated as an afterthought rather than an architecture decision
EU MDR and CE marking obligations understood on paper but not embedded in engineering practice
Cross-border health data governance that would not survive scrutiny under EHDS or national DPA audit
Regulatory compliance built for one jurisdiction, with no plan for the next
From Digital Therapeutics to Clinical AI
Our healthtech experience is not theoretical. We have held fractional CTO positions across the breadth of healthcare technology, and conducted audits and due diligence assessments on many more.
We have led technology for platforms that combine clinical services with digital delivery: online pharmacy, telehealth, remote monitoring, and AI-powered diagnostics. We have built and scaled care management platforms used across residential, domiciliary, and supported living settings. We have worked with clinical decision support systems that put information in front of clinicians at the point of care, where latency and accuracy are not trade-offs but joint requirements.
Digital therapeutics, surgical AI, mental health platforms, respiratory diagnostics, waiting list management: each of these brings its own regulatory surface and its own technical constraints. In a European context, the challenge intensifies. A digital health application assessed under Germany's DiGA framework faces different evidence requirements than one seeking HAS approval in France or NHS adoption in the UK. A medical device carrying a CE mark under EU MDR 2017/745 must meet different post-market surveillance obligations than one regulated under UK MDR 2002 by the MHRA.
The EU AI Act adds a further dimension. Clinical AI systems fall squarely within the high-risk classification under Annex III, triggering requirements for conformity assessment, human oversight, transparency, and ongoing monitoring that go well beyond traditional medical device regulation. For healthtech companies deploying AI in clinical settings across Europe, the intersection of EU MDR and the AI Act creates a regulatory surface that few technology leaders have encountered before.
We have built and led healthcare technology spanning pharmacy, social care, medical devices, telemedicine, digital health, mental health, and national health services. That breadth of pattern recognition is what we bring to every new engagement, whether we are stepping in as fractional CTO, conducting a technology audit for an investor, coaching a first-time CTO through their first integration with a national health system, or assessing AI capabilities in a clinical setting.
How We Help
Fractional CTO for HealthTech
Hands-on technology leadership for healthcare companies operating across European markets. We embed with your team and own the technology strategy, architecture, and delivery, whether you call the role CTO, Interim CTO, or DSI de transition.
HealthTech Due Diligence
Technology assessment for investors evaluating healthcare companies across jurisdictions. We assess clinical safety compliance, health data governance, EU MDR readiness, AI Act implications, and the team's ability to operate in a multi-regulator environment.
CTO Coaching and Advisory
For healthtech CTOs navigating European regulation for the first time. Practical guidance on CE marking, clinical safety cases, EHDS readiness, national health system integration, and building engineering teams that can ship across borders.
European Health Regulation: Depth Across Jurisdictions
Our partners have direct, operational experience with the regulatory frameworks that govern healthcare technology across Europe. This is not consulting knowledge. It is the result of building systems that had to meet these requirements to go live.
EU MDR 2017/745 and IVDR. We understand the CE marking pathway for medical devices and in vitro diagnostics, from classification and conformity assessment through to post-market surveillance. For software as a medical device (SaMD), the boundary between regulated product and general wellness tool is a critical architectural decision. We know where that line sits and what crossing it means for your engineering process, your quality management system, and your time to market.
European Health Data Space (EHDS). The EHDS is transforming how health data is governed, shared, and reused across the EU. We help healthtech companies assess the implications for their data architecture, consent models, and cross-border data flows, before compliance becomes mandatory rather than aspirational.
National Health System Frameworks. We have operated within and integrated with national health systems where the requirements differ substantially. NHS Digital standards (DCB 0129, DCB 0160, DSPT) for the UK. BfArM and DiGA requirements for Germany. HAS evaluation frameworks for France. HPRA and HIQA requirements for Ireland. Each jurisdiction has its own onboarding, assurance, and integration pathway. We understand the practical differences, not just the regulatory text.
EU AI Act: High-Risk Clinical AI. Clinical AI systems are classified as high-risk under Annex III of the EU AI Act. This triggers conformity assessment, mandatory human oversight, transparency obligations, and ongoing monitoring requirements. For healthtech companies deploying AI in diagnostic, treatment planning, or clinical decision support, the intersection of EU MDR and the AI Act creates compliance obligations that must be addressed at the architecture level, not bolted on after launch.
GDPR Across National Authorities. Health data is special-category data under GDPR, but how national authorities interpret and enforce the regulation varies. The CNIL, BfDI, Garante, AP, and Irish DPC each bring different expectations around consent, data minimisation, and cross-border transfers. We have built systems that satisfy these requirements in practice, not just on paper.
Why Rational Partners for HealthTech
Regulated Sector Operators
Our partners have held CTO positions in healthcare companies. They have built the systems, passed the assessments, and managed clinical safety relationships across jurisdictions. This is operational experience, not advisory.
Cross-Border Regulatory Fluency
EU MDR, IVDR, EHDS, the AI Act, DiGA, HAS, NHS Digital. We assess regulated healthtech across European frameworks and understand the practical differences between them, not just the acronyms.
Investor and Founder Perspective
We conduct healthtech due diligence for PE and VC investors across Europe, and we serve as fractional CTO for the companies they invest in. We understand both sides of the table, in every jurisdiction.
Frequently Asked Questions
30-minute initial discussion to understand your requirements, regulatory landscape, and key technical concerns across your European healthtech operations.